Implements Change-in-Control Retention Arrangements for Employees
RALEIGH, N.C., Nov. 16, 2017 -- Triangle Capital Corporation (NYSE:TCAP) (the “Company”) today announced that it has engaged Houlihan Lokey as its financial advisor to assist the Company’s board of directors in exploring and evaluating a broad range of strategic alternatives to enhance long-term shareholder value.
Concurrent with the engagement of a financial advisor, the compensation committee of the Company’s board of directors approved change-in-control retention arrangements for the Company’s employees in order to ensure continuity of its business and its employees through the completion of the strategic alternatives review process and any related transactions.
About Triangle Capital Corporation
Triangle Capital Corporation (www.tcap.com) invests capital in established companies in the lower middle market to fund growth, changes of control and other corporate events. It offers a wide variety of debt and equity investment structures including first lien, unitranche, second lien, and mezzanine with equity components. Triangle Capital’s investment objective is to seek attractive returns by generating current income from debt investments and capital appreciation from equity related investments. Triangle Capital’s investment philosophy is to partner with business owners, management teams and financial sponsors to provide flexible financing solutions. Triangle Capital typically invests $5.0 million to $50.0 million per transaction in companies with annual revenues between $20.0 million and $300.0 million and EBITDA between $5.0 million and $75.0 million.
Triangle Capital has elected to be treated as a business development company under the Investment Company Act of 1940 and a regulated investment company under the Internal Revenue Code of 1986.
Forward-Looking Statements
This press release contains forward-looking statements, including with regard to the Company’s review of certain strategic alternatives and any expected or anticipated benefits from the foregoing review process. These statements are not guarantees of future events and involve risks and uncertainties that are difficult to predict. As a result, there can be no assurance that this process will result in a transaction, or if a transaction is undertaken, as to its terms or timing.
In addition, actual results could differ materially from those expressed or implied by the forward-looking statements as a result of various factors, including the factors discussed in the Company’s annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and other documents or reports that the Company in the future may file with the SEC.
The Company has not set a definitive schedule to complete its review of strategic alternatives and does not intend to provide updates until such time as it determines in its sole discretion, as required by law, and/or it has entered into definitive documentation with respect to any strategic transaction.
Contacts
E. Ashton Poole
Chairman & Chief Executive Officer
919-747-8618
[email protected]
Steven C. Lilly
Chief Financial Officer
919-719-4789
[email protected]


TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Instagram Outage Disrupts Thousands of U.S. Users
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Washington Post Publisher Will Lewis Steps Down After Layoffs
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Ford and Geely Explore Strategic Manufacturing Partnership in Europe
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 



